2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100897
    Sulodexide 57821-29-1
    Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease. Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.
    Sulodexide
  • HY-107382
    RF9 876310-60-0 99.37%
    RF9 is a potent and selective Neuropeptide FF receptor antagonist, with Ki values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.
    RF9
  • HY-145742
    1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol sodium 200880-42-8 98.0%
    1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol (sodium) is the component of liposomes for drug delivery.
    1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol sodium
  • HY-P99555
    Tomaralimab 1449294-76-1 99.42%
    Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury.
    Tomaralimab
  • HY-12424
    Zotarolimus 221877-54-9 ≥98.0%
    Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis.
    Zotarolimus
  • HY-13221
    BRL 54443 57477-39-1 98.97%
    BRL 54443 is a potent 5-HT1E/1F receptor agonist (Ki values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.
    BRL 54443
  • HY-18990
    GSK180736A 817194-38-0 98.81%
    GSK180736A is potent Rho-associated coiled-coil kinase 1 (ROCK1) inhibitor with an IC50 of 100 nM. GSK180736A is also a selective and ATP-competitive G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM.
    GSK180736A
  • HY-33350
    Clofilium tosylate 92953-10-1 99.60%
    Clofilium tosylate, a potassium channel blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Antiarrhythmic agent.
    Clofilium tosylate
  • HY-50737
    DUB-IN-3 924296-17-3 99.00%
    DUB-IN-3 (compound 22c) is a potent and selective inhibitor of the deubiquitinating enzyme USP8 with an IC50 value of 0.56 μM. DUB-IN-3 is promising for research of cancer, neurodegenerative diseases, inflammation, viral infection and cardiovascular disease.
    DUB-IN-3
  • HY-B1183
    Hydrocortisone acetate 50-03-3 99.14%
    Hydrocortisone acetate (Hydrocortisone 21-acetate) is a corticosteroid used to reduce swelling, itching and pain caused by minor skin irritations or hemorrhoids.
    Hydrocortisone acetate
  • HY-B1276
    Metaproterenol hemisulfate 5874-97-5 99.83%
    Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist with an IC50 of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.
    Metaproterenol hemisulfate
  • HY-B1481
    Isoetharine mesylate 7279-75-6 99.05%
    Isoetharine (Isoetarine) mesylate is an orally active selective agonist of β-adrenergic receptors. Isoetharine mesylate is a catechol-like agent and catechol O-methyltransferase (COMT) mediates its methylation. Isoetharine mesylate can promote the production of cAMP which stimulates the relaxation of smooth muscle cells and can be used as an emphysema, bronchitis and bronchodilator.
    Isoetharine mesylate
  • HY-B1555
    Benzyl nicotinate 94-44-0
    Benzyl nicotinate is a vasodilator that increases skin oxygenation levels by increasing skin blood flow.
    Benzyl nicotinate
  • HY-N0126
    Xanthone 90-47-1 99.97%
    Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K+-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca2+ channels. Xanthone is the scaffold of several pharmacologically active compounds.
    Xanthone
  • HY-N0885
    Telocinobufagin 472-26-4 99.93%
    Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na+/K+-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models.
    Telocinobufagin
  • HY-N1356
    Reticuline 485-19-8 98.91%
    Reticuline shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.
    Reticuline
  • HY-N2007
    Veratric acid 93-07-2 ≥98.0%
    Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant and anti-inflammatory activities. Veratric acid also acts as a protective agent against hypertension-associated cardiovascular remodelling. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation.
    Veratric acid
  • HY-N2165
    Vicenin 2 23666-13-9 99.77%
    Vicenin 2, a flavonoid, is an orally active angiotensin-converting enzyme (ACE) inhibitor (IC50 of 43.83 μM). Vicenin 2 has radioprotective, anti-nociceptive effects, anti-glycation anti-inflammatory, antioxidant, anticancer, antiangiogenic properties.
    Vicenin 2
  • HY-N2481
    Oroxylin A-7-O-glucuronide 36948-76-2 99.83%
    Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities.
    Oroxylin A-7-O-glucuronide
  • HY-N6066
    Praeruptorin E 78478-28-1 99.83%
    Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD2′ value of 5.2.
    Praeruptorin E
Cat. No. Product Name / Synonyms Application Reactivity